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Abstract
Background: Estradiol (E2) mediates various intracellular signaling cascades from the plasma
membrane via several estrogen receptors (ERs). The pituitary is an estrogen-responsive tissue, and
we have previously reported that E2 can activate mitogen-activated protein kinases (MAPKs) such
as ERK1/2 and JNK1/2/3 in the membrane ERα (mERα)-enriched GH3/B6/F10 rat pituitary tumor
cell line. Phytoestrogens are compounds found in plants and foods such as soybeans, alfalfa sprouts,
and red grapes. They are structurally similar to E2 and share a similar mechanism of action through
their binding to ERs. Phytoestrogens bind to nuclear ERs with a much lower affinity and therefore
are less potent in mediating genomic responses. However, little is known about their ability to act
via mERs to mediate nongenomic effects.
Methods: To investigate the activation of different nongenomic pathways, and determine the
involvement of mERα, we measured prolactin (PRL) release by radio-immunoassay, MAPK
activations (ERK1/2 and JNK1/2/3) via a quantitative plate immunoassay, and intracellular [Ca2+] by
Fura-2 fluorescence imaging in cells treated with E2 or four different phytoestrogens (coumestrol,
daidzein, genistein, and trans-resveratrol).
Results: Coumesterol and daidzein increased PRL release similar to E2 in GH3/B6/F10 cells, while
genistein and trans-resveratrol had no effect. All of these compounds except genistein activated
ERK1/2 signaling at 1–10 picomolar concentrations; JNK 1/2/3 was activated by all compounds at a
100 nanomolar concentration. All compounds also caused rapid Ca2+ uptake, though in unique
dose-dependent Ca2+ response patterns for several aspects of this response. A subclone of GH3
cells expressing low levels of mERα (GH3/B6/D9) did not respond to any phytoestrogen treatments
for any of these responses, suggesting that these nongenomic effects were mediated via mERα.
Conclusion: Phytoestrogens were much more potent in mediating these nongenomic responses
(activation of MAPKs, PRL release, and increased intracellular [Ca2+]) via mERα than was previously
reported for genomic responses. The unique non-monotonic dose responses and variant signaling
patterns caused by E2 and all tested phytoestrogens suggest that complex and multiple signaling
pathways or binding partners could be involved. By activating these different nongenomic signaling
pathways, phytoestrogens could have significant physiological consequences for pituitary cell
functions.
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Background
Binding of 17β-estradiol (E2) to estrogen receptors (ERs)
elicits important changes in growth, differentiation, mat-
uration, and other functions of target tissues [1-4]. In the
pituitary, E2 and its pharmaceutical mimic diethylstilbes-
terol (DES) have many effects, including proliferation of
several pituitary cell types, formation of new blood vessels
[5], regulation of most pituitary hormones [6], and tum-
origenesis [7]. For some of these effects, the ERs α and β
function as ligand-dependent transcription factors con-
trolling expression of responsive genes upon activation.
However, there are now numerous studies showing that
E2 can rapidly influence cellular physiology in pituitary
and many other cell types via the activation of a diverse
array of intracellular non-nuclear signaling mechanisms
[4,8,9]. For example, E2 can rapidly increase intracellular
Ca2+ or activate extracellular regulated kinases (ERK1/2)
[10,11]. Although the complete mechanistic details of
these nongenomic actions are not fully understood, it is
known that some of the rapid E2 effects are initiated by
binding of E2 at membrane-associated ERs that are closely
related to the "classical" intracellular ERs [12-14].
Phytoestogens are a group of lipophilic plant compounds
that are structurally similar to E2 and have been shown to
bind to ERs (α and β) and the alternative ER, GPR30 [15-
17]. Both genomic and nongenomic mechanisms have
been proposed to mediate phytoestrogenic effects. Phy-
toestrogens can bind to ERs and induce expression of spe-
cific estrogen-responsive gene products in conjunction
with regulating cellular processes such as growth and dif-
ferentiation [18,19]. We found previously that coumes-
terol, a phytoestrogen with relatively high estrogenic
potency for nuclear actions [20], can also initiate signal-
ing from the membrane such as activation of ERK1/2, PRL
release, and changes in Ca2+ fluxes [21,22] in rat pituitary
cells. Rapid activations by both E2 and phytoestrogens via
mERs have also been reported in other tissues, such as
brain [23]. In the present study, we extend these observa-
tions to several other phytoestrogens, in comparison to E2
and coumesterol. Coumesterol can disrupt reproduction
in livestock [24], where its major dietary sources are leg-
umes, clover, and alfalfa sprouts. Serum concentrations of
coumesterol can be as high as 0.01 μM in humans [25].
The popular food supplements isoflavones are soybean
components, and are represented by daidzein and genis-
tein in our studies. Differences between Western and
Asian diets may underlie the population variations in the
incidence of estrogen-influenced cancers and other dis-
eases in a variety of tissues [26]. Consumption of Asian-
style diets enriched in these soybean products can lead to
plasma concentrations of isoflavonoids of 0.1 to 10 μM
[20,25]. Resveratrol, a stilbene which is found in high
quantities in foods such as red grapes (and wine) and pea-
nuts has two isomers (cis and trans), but only the trans
form has been reported to be estrogenic [27]. There is
growing evidence that resveratrol may prevent or delay the
onset of cancer, heart disease, diabetes, pathological
inflammations and viral infections [28]. The human
serum concentrations of resveratrol and its metabolites
are variable, but can peak at close to 2 μM [29].
Nongenomic effects caused by phytoestrogens could play
a key role in a variety of biological functions by altering
membrane-initiated signaling patterns. E2-mediated acti-
vation of kinases in the MAPK family (including ERK1/2
and JNK1/2/3) can change the complex partnering of ERs
with other kinases, such as Src and Ras [30]. In addition,
downstream cytoplasmic or transcriptional events have
been attributed to activation of MAPKs [31]. E2 can also
rapidly regulate intracellular Ca2+ levels [11,32], impor-
tant for triggering release of secretory granules, maintain-
ing homeostatic functions and regulating other estrogen-
induced kinase changes [33]. A rapid, stimulatory effect of
E2 on prolactin (PRL) secretion could affect milk produc-
tion, osmoregulation, and maternal behaviors [6]. In the
current study we used a wide range of concentrations of
different phytoestrogens to elicit rapid kinase activations,
PRL release, and elevation of intracellular [Ca2+] in the
mERα-enriched rat pituitary cell line GH3/B6/F10 [34]. We
also examined the involvement of mERα by comparing
these nongenomic responses in the mERα-depleted cell
line GH3/B6/D9. Our elucidation of the distinct abilities of
different phytoestrogens to activate these nongenomic sig-
naling pathways in different dose-response patterns could
predict the physiological consequences of these com-
pounds as dietary components or hormone replacement
supplements.
Methods
Materials and Cells
We purchased phenol red-free Dulbecco Modified Eagle
Medium (DMEM) from Mediatech (Herndon, VA); horse
serum from Gibco BRL (Grand Island, NY); defined sup-
plemented calf sera and fetal bovine sera from Hyclone
(Logan, UT). Paraformaldehyde and glutaraldehyde were
purchased from Fisher Scientific (Pittsburgh, PA). We pur-
chased Fura-2 AM from Molecular Probes (Eugene, OR).
Antibodies (Abs) used in the ERK and JNK phosphoryla-
tion studies (individually described below) were pur-
chased from Cell Signaling (Danvers, MA). All other
materials were purchased from Sigma (St. Louis, MO).
GH3/B6/F10  (mERα-enriched) and GH3/B6/D9  (mERα-
poor) cell sublines [34] were routinely cultured in DMEM
containing 12.5% horse serum, 2.5% defined supple-
mented calf serum, and 1.5% fetal calf serum. They were
then switched to various hormone-free media prior to our
experiments, as described below. Cells were used between
passages 10 and 20.Journal of Molecular Signaling 2009, 4:2 http://www.jmolecularsignaling.com/content/4/1/2
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PRL release measured via RIA
Cells (0.5–0.7 × 106) were plated in poly-D-lysine-coated
six-well plates. After serum deprivation in ITS defined
medium [5 μg/mL insulin, 5 μg/mL transferring, 5 ng/mL
sodium selenite, and 0.1% bovine serum albumin (BSA)]
for 48 h, this medium was removed and DMEM/0.1%
BSA was added with or without the appropriate estrogen
or vehicle control (ethanol). The cells were incubated for
2 min and centrifuged at 4°C (350 × g for 5 min), then the
supernatant was collected and stored at -20°C. The PRL
concentrations were determined using components of the
rat PRL RIA kit from the National Institute of Diabetes and
Digestive and Kidney Disease and the National Hormone
and Pituitary Program (Baltimore, MD). Briefly, RIA
buffer [80% phosphate-buffered saline (PBS), 20%
DMEM, 2% normal rabbit serum], 100 μL cold standard
(rat PRL-RP-3) or unknown sample, rPRL-s-9 antiserum
(final dilution of 1:437,500 in RIA buffer), and [125I]-rat-
PRL (PerkinElmer, Wellesley, MA, USA; using 15,000
counts per tube diluted in RIA buffer) were combined and
incubated with shaking overnight at 4°C. Anti-rabbit IgG
(R-0881; Sigma) was added to a final dilution of 1:9, and
the samples were incubated with shaking at RT for 2 h.
One mL of polyethylene glycol solution [1.2 M polyethyl-
ene glycol (P-6667; Sigma), 50 mM Tris, pH 8.6] was then
added, the samples were incubated with shaking at RT for
15 min, then centrifuged at 4,000 × g for 10 min at 4°C.
The supernatant was decanted, and the pellet counted in
a Wizard 1470 Gamma Counter (PerkinElmer, Boston,
MA). The PRL concentration was then calculated and nor-
malized to the crystal violet (CV) values estimating the
number of cells in each well [35]. To perform the CV assay
cells were stained with 0.1% CV solution and incubated at
room temperature for 30 min, then washed with PBS and
dried. The dye was then extracted with 10% acetic acid
solution and read at A590 nm. These measurements (n = 6)
were done in 3 different experiments on different days.
ERK and JNK assays
We originally developed this assay to assess activated ERK
1/2 levels in fixed GH3/B6 cell subclones [10], and subse-
quently adapted it to equivalent assays for JNK1/2/3.
Briefly, cells were plated at a density of 10,000 cells/well
in poly-D-lysine-coated 96-well plates. Growth media
were replaced on the following day (for 48 h) with DMEM
containing 1% charcoal-stripped (4×) serum (to deprive
cells of steroids). Cells were then washed with DMEM
once before the estrogens (or 0.0001% ethanol vehicle)
were added for 5 (ERK) or 15 min (JNK). The cells were
then fixed with 2% paraformaldehyde/0.2% picric acid at
4°C for 48 h. After fixation, the cells were permeabilized
with PBS containing 2% BSA and 0.1% Triton X-100 for 1
h at RT, then washed 3× with PBS; primary antibody (Ab)
against phosphorylated ERKS (Cell Signaling Technology,
p-Thr202/Tyr204; 1:400 in PBS/1% BSA) or phosphor-
ylated JNK (Cell Signaling Technology, p-Thr183/Tyr185;
1:500 in PBS/1% BSA) was then added. After overnight
incubation at 4°C, the cells were washed 3× with PBS, and
the biotin-conjugated secondary Ab (Vector Labs, Burlin-
game CA, 1:300) in PBS/1% BSA was added for 1 h at RT.
The cells were again washed with PBS, incubated with
Vectastain ABC-AP solution (Vector Labs) for 1 h at RT,
and again washed 3× with PBS, followed by addition of
Vectastain alkaline phosphatase substrate plus levamasole
(an endogenous phosphatase inhibitor). Plates were incu-
bated in the dark for 30 min at 37°C, and the signal for
the phosphatase product para-nitrophenol was read at
A405 in a model 1420 Wallac microplate reader (Perkin
Elmer, Waltham, MA). The number of cells in each well
was estimated by the CV assay and used to normalize
phosphorylated enzyme values in individual wells. The
experiments (n = 8) were repeated at least 3 times using
different passages of cells on different days.
Ca2+ imaging
Cells were plated on poly-D-lysine-treated 35/22 mm
glass-bottom dishes (Willco Wells, Amsterdam, Nether-
lands) at a density of 100,000 cells/mm3. After 48–72 h,
the cells were incubated in serum-free DMEM for 12 h
before being loaded with 2.5 μM of the Ca2+-sensitive flu-
orescent dye Fura-2 AM for 1 h at RT. They were then
washed 3 times, and incubated at RT for 1–4 h before live
Ca2+  imaging experiments. The physiological solution
used for Fura-2 AM loading and live-cell imaging con-
tained 150 mM NaCl, 5.5 mM KCl, 1 mM MgCl2, 4 mM
CaCl2, 7 mM glucose, and 10 mM HEPES, pH 7.4.
The cell imaging setup included a Nikon 200E microscope
with 40× SuperFluo lens and computer-controlled illumi-
nation system (Sutter Instruments, Novato, CA) equipped
with a digital monochrome-cooled charge-coupled device
Roper Coolsnap HQ camera (Roper Scientific, Tucson,
AZ).
Fluorescent emissions at 510 nm were acquired from
regions corresponding to a single cell with the MetaFluor
software (Universal Imaging, Downington, PA) using
dual 340 and 380 nm excitation mode. The average inten-
sity of fluorescence in each region was used to estimate
340:380 ratios (R), reflecting [Ca2+].
MetaMorph (Universal Imaging, Downington, PA) and
SigmaPlot (Systat Software, San Jose, CA) scientific soft-
ware were used for conversion and analysis of acquired
data. The AutoFit function of PeakFit software (Systat Soft-
ware, San Jose, CA) with manual adjustments was used to
quantitatively characterize Ca2+  oscillation amplitude,
volume, and frequency in live cells. The peak threshold
was chosen empirically as ΔR ≥0.05. Individual cells were
considered responsive to hormone treatments when theyJournal of Molecular Signaling 2009, 4:2 http://www.jmolecularsignaling.com/content/4/1/2
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demonstrated an increase in Ca2+ oscillation frequency
compared to basal, showed at least 0.25 Ca2+ spikes per
min as estimated over a 10 min time interval, and with a
delay of no more than 10 min from the addition of each
estrogen into the bath. Subsequent comparative analysis
of cell responses was performed on these defined respon-
sive cells only. The experiments were repeated using dif-
ferent passages of cells on different days. Ca2+ traces of at
least 30 cells were examined for each condition.
Statistics
Data from MAPK assays and intracellular Ca2+ measure-
ments were analyzed by one-way analysis of variance
(ANOVA) followed by multiple comparisons vs. control
group (Holm-Sidak method for MAPK assay; Dunnett's
and Duncan's method for intracellular Ca2+). The Sigma
Stat 3 program (Systat Software, Inc.) was used for all sta-
tistical analysis, and significance was accepted at p < 0.05.
Results
PRL release caused by E2 and different phytoestrogens 
(Figure 1)
E2 caused a rapid (2 min) PRL release in GH3/B6/F10 cells
at concentrations of 10-11 M–10-7 M (except at 10-10 M).
Among the phytoestrogens, only coumesterol (at 10-11–
10-8 M concentrations) and daidezin (at 10-10–10-6 M con-
centrations, except 10-8 M) significantly increased PRL
release. Note the interruption of effective doses by an inef-
fective dose, as we have seen previously [22,36]. Genistein
and  trans-resveratrol did not significantly change PRL
release at any concentration tested. In Figure 1 and all fol-
lowing figures showing concentration ranges for
responses, the horizontal bars on the graphs depict the
range of concentration of these compounds that have
been measured in human serum or urine.
Phosphorylation of ERK1/2 caused by E2 and different 
phytoestrogens (Figure 2)
E2  and phytoestrogens activated ERK phosphorylation
with unique concentration-dependent patterns. At con-
centrations of 10-14–10-8 M (except 10-10 M), E2 caused a
rapid activation of ERKs within 5 min. The maximum
responses occurred at 10-13 and 10-9 M concentrations.
Unlike E2, coumesterol and trans-resveratrol only
increased phosphorylation of ERKs at one range of con-
centrations (10-12–10-10 M or 10-12–10-9 M, respectively).
Daidzein, like E2, activated ERKs at 10-11–10-7 M, but with
slight shifts in effective doses. The closely related soy phy-
toestrogen genistein did not change phosphorylation of
ERKs at any concentration examined.
Phosphorylation of JNK1/2/3 by E2 and different 
phytoestrogens (Figure 3)
All estrogens increased phosphorylation of a family of
JNKs (1/2/3) within 15 minutes, with E2 being the most
PRL release induced by phytoestrogens Figure 1
PRL release induced by phytoestrogens. Measurements 
of PRL (by RIA) released into the media after 2 minutes of 
treatment with different concentrations of estrogens: estra-
diol (E2), coumesterol (Cou), daidzein (Dai), genistein (Gen), 
and trans-resveratrol (Res). The solid horizontal line indicates 
the range of serum and/or urine concentrations of each phy-
toestrogen found in humans. * = p < 0.05 compared to vehi-
cle treated-cells (Con).
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ERK phosphorylation induced by phytoestrogens Figure 2
ERK phosphorylation induced by phytoestrogens. 
Quantitative plate assay measurements of phosphorylated 
ERKs 1 and 2 after 5 minutes of treatment with different 
concentrations of estrogens: estradiol (E2), coumesterol 
(Cou), daidzein (Dai), genistein (Gen), and trans-resveratrol 
(Res). The solid horizontal line indicates the range of serum 
and/or urine concentrations of each phytoestrogen found in 
humans. * = p < 0.05 compared to vehicle treated-cells 
(Con).
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JNK phosphorylation induced by phytoestrogens Figure 3
JNK phosphorylation induced by phytoestrogens. 
Quantitative plate assays of phosphorylated JNKs 1, 2 and 3 
after 15 minutes of treatment with different concentrations 
of estrogens: estradiol (E2), coumesterol (Cou), daidzein 
(Dai), genistein (Gen), and trans-resveratrol (Res). The solid 
horizontal line indicates the range of serum and/or urine con-
centrations of each phytoestrogen found in humans. * = p < 
0.05 compared to vehicle treated-cells (Con).
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potent at this activity (responding at concentrations as
low as 10-13 M). However, again a single intermittent con-
centration (10-11 M) did not show a significant elevation.
Coumesterol, daidzein, genistein, and trans-resveratrol
increased phosphorylation of JNKs maximally only in the
higher concentration ranges (10-8–10-6 M).
E2 and different phytoestrogens cause Ca2+ influx
Approximately 20–40% of the cells showed Ca2+ influx in
response to E2 treatment regardless of the concentration
(10-15-10-9 M) used (Figure 4); a similar range of cells
responded to coumesterol treatment (10-10–10-7 M), but
with larger variations between concentrations. Coumes-
terol caused Ca2+ influx in the highest number of cells
(60%) at the highest concentration (10-7 M). For daidzein,
only the 10-8–10-7 M treatments caused 20–40% of cells to
respond. For genistein, only the 10-9 M and 10-7 M con-
centrations caused Ca2+ influx in 20–40% of cells, but not
the intervening 10-8 M concentration.Trans-resveratrol at
concentrations of 10-10–10-7 M caused Ca2+ influx in only
~20% of cells, again with an intervening lack of response
at 10-9 M. Treatments with both E2 (at 10–15-10-9 M) and
coumesterol (at 10-10–10-7 M) significantly increased the
Ca2+ oscillation frequency from 0.4 to 1.5 per min at all
concentrations examined (Figure 5). Daidzein, genistein,
and trans-resveratrol also increased Ca2+ oscillation fre-
quencies at most, but not all concentrations tested. Again,
some intermittent concentrations were not effective. The
total volume of the Ca2+ influx was measured by adding
together the total areas under the in Ca2+ curves for 10 min
after treatments (Figure 6). All estrogens caused an
increase. For both E2 and coumesterol this increase was
seen at all concentrations examined. Daidzein, genistein,
and trans-resveratrol responded at many but not all con-
centrations, again demonstrating the non-monotonic
nature of the responses.
Rapid nongenomic responses to phytoestrogens and E2 are 
mediated via the mERα (Figure 7)
GH3 cell sublines with low (D9) or enriched (F10) levels of
mERα [34,37] showed the expected results for a response
dependent upon mERα. The most effective concentrations
Figure 4
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Percentage of cells showing Ca2+ influx triggered by 
phytoestrogens. Fura-2 analyses of the percentage of cells 
showing a Ca2+ influx response to treatment with different 
concentrations of estrogens: estradiol (E2), coumesterol 
(Cou), daidzein (Dai), genistein (Gen), and trans-resveratrol 
(Res). The solid horizontal line indicates the range of serum 
and/or urine concentrations of each phytoestrogen found in 
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Effects of phytoestrogens on Ca2+ oscillation Figure 5
Effects of phytoestrogens on Ca2+ oscillation. Fura-2 
measurements of Ca2+ oscillation frequency in cells treated 
with different concentrations of estrogens: estradiol (E2), 
coumesterol (Cou), daidzein (Dai), genistein (Gen), and 
trans-resveratrol (Res). The solid horizontal line indicates the 
range of serum and/or urine concentrations of each phytoes-
trogen found in humans. * = p < 0.05 compared to vehicle-
treated cells (Con).
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for each compound for each of the measured responses
(PRL release, phosphorylation of ERKs, phosphorylation
of JNKs, and percentage of cells showing a Ca2+ response)
was used (see Figures 1, 2, 3, 4, 5, 6); each phytoestrogen
that had previously evoked a response in F10 cells did here
as well. However, D9 cells could not respond, as expected.
Regardless of subclone lineage, the cells are spontane-
ously active, and respond with a complete Ca2+ response
upon KCl depolarization [11]. We also demonstrated that
the mERα-dependence for kinase activations affected only
the response to estrogens, as 20 nM TPA (phorbol 12-myr-
istate 13-acetate) caused phosphorylation of ERKs and
JNKs for both sublines, regardless of mERα status.
Discussion
Rapid non-genomic effects caused by E2 are now well doc-
umented in various tissues [9,23,38]; however, those
caused by phytoestrogens are little studied. Here we exam-
ined the estrogenic activity of four different phytoestro-
gens commonly available in foods and as food
supplements, and demonstrated their abilities to mediate
nongenomic actions (rapid PRL release, phosphorylation
of ERKs and JNKs, and rapid increases of intracellular Ca2+
levels) in a rat pituitary tumor cell line. We also estab-
lished a role for mERα in these rapid effects by phytoestro-
gens by using sublines enriched and depleted for mERα.
Like E2, coumesterol and daidzein elicited PRL release at
low concentrations, such as those easily attainable in
human diets [20,25,27,39]. However, genistein and trans-
resveratrol were ineffective at all concentrations examined
for this response. Although daidzein and genistein are
from the same food source and are similar in structure,
they bind to ERs with different affinities [40]. Genistein
also has effects that are not mediated through ERs, such as
inhibition of tyrosine kinases [41], which could alter
these signaling pathways through a complex web of sign-
aling interactions. Trans-resveratrol can also activate AMP-
activated enzymes during caloric restriction [42], and may
therefore also initiate other signaling cascades that would
impact the signaling machinery that we have focused on
here. Thus other responses to these compounds not medi-
ated by ERs could also come into play, depending upon
the specific concentrations, and so influence many of the
dose-response curves shown here that appear to be non-
traditional in shape. It is now becoming commonly
accepted that the "web" of signaling outside the focus of
individual measurements must be considered when
examining these types of responses.
MAPKs control many aspects of mammalian cellular
physiology, including cell growth, differentiation and
apoptosis. They are well known for responding to
mitogens, growth factors (such as epidermal growth fac-
tor), and stress [31,43]. We recently demonstrated that
Involvement of mERα in nongenomic effects by phytoestro- gens Figure 7
Involvement of mERα in nongenomic effects by phy-
toestrogens. Comparison of mERα-depleted subclone D9 
(open bars) with mERα-enriched subclone F10 cells (solid 
bars) treated with different estrogens: estradiol (E2), cou-
mesterol (Cou), daidzein (Dai), genistein (Gen), and trans-
resveratrol (Res). (A) PRL released, (B) ERK activation, (C) 
JNK activation, and (D) % of cells showing Ca2+ influx. * = p < 
0.05 compared to vehicle-treated cells (Con).
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other estrogens (both physiological and environmental)
can rapidly activate ERKs via mERα and non-genomic
pathways in GH3/B6/F10 cells [11,21]. Now several exam-
ples from another class of estrogens examined here, phy-
toestrogens, also increased phosphorylation of ERKs,
similar to E2. Trans-resveratrol had previously been shown
to activate ERKs in endothelial cells [44]. Compared to E2,
which phosphorylated JNKs at sub-picomolar concentra-
tions, these phytoestrogens were less potent, but the acti-
vating concentrations required were still well within
dietary intake ranges (10-8–10-7  M). Activating these
MAPKs could lead to changes in both of the opposing
effects of cell replication or apoptosis in pituitary cells,
depending upon concentrations and combinations, but
the precise roles for each of these MAPKs are still unclear
[45,46]. It is interesting that the responses of ERKs and
JNKs had different sensitivities to this group of estrogens,
with JNKs only responding at higher concentrations. If
these enzymes were to function differentially in prolifera-
tive vs. apoptotic pathways, then such a change in the bal-
ance of these competing functions could have profound
effects on cell number.
The comparisons between estrogenic compounds' control
of intracellular Ca2+ levels were more complex. Most of
the phytoestrogens evoked E2-like numbers of responding
cells, Ca2+ oscillation frequencies, and influx volumes,
though E2 and coumesterol were more potent. Neverthe-
less, the effective concentration ranges of phytoestrogens
were those found in human serum or urine. Because L-
type Ca2+ channel blockers abrogate coumesterol-induced
Ca 2+ influx and PRL release [22], other phytoestrogens
may do so via the same receptors and mechanisms. Sort-
ing out the exact mechanisms will require using tech-
niques such as patch-clamp recording of Ca2+ currents.
The non-monotonic characteristics of these responses
were similar to those we have reported earlier for other
estrogens, both physiological and estrogenic environmen-
tal contaminants [22,36]. As there are currently disputes
in the literature about the effects of phytoestrogens, it is
important to study their effects over a wide range of con-
centrations. These unique dose-response patterns suggest
that multiple signaling pathways, receptor couplings, or
activations of competing kinases/phosphatases could be
involved [6,47,48]. Phytoestrogen exposures and the
resulting plasma concentrations vary substantially across
human populations and individuals [49] because of
genetic variations, differences in dietary intake, and local
differences in the phytoestrogen content in plants. The
bioavailability of processed phytoestrogens in the gut is
also quite different; for example, the total plasma levels of
isoflavonoids and lignans in humans range from 10–400
nM, and plasma levels can peak at 2 μM within a few
hours of food consumption. There are also reports of indi-
vidual variations in tissue accumulation of these phytoes-
trogens such as in prostate [50], and sex variations (female
rats show 2.5 times higher concentrations of genistein in
liver than males [51] administered the same amounts).
These considerations may be important for dosing
amounts and schedules if these compounds are to be used
effectively as therapeutics.
Conclusion
Phytoestrogens have rapid and relatively potent non-
genomic effects on pituitary cells, apparently mediated via
mERα. The concentrations required to activate these
effects could easily be attained by dietary levels, and are
lower than those required to activate genomic mecha-
nisms. Further knowledge of the multiple factors affecting
these responses should include comprehensive examina-
tion of the multiple intersecting signaling pathways likely
to be evoked. Their usefulness as safe, effective, and inex-
pensive estrogen replacement therapeutics will have to be
carefully considered for each compound individually, as
well as how they act in combinations with other dietary,
endogenous, and environmental estrogens. Since PRL-
secreting adenomas are the most prevalent form of pitui-
tary tumors in human and they contain high levels of ERα
mRNA and protein [52], these studies may have implica-
tions for the influence of phytoestrogens on the behavior
of both normal and tumor tissues.
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